Open Label High Dose Ropinirole (Requip) Study for Patients With Parkinson's Disease
NCT ID: NCT00260793
Last Updated: 2006-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
20 participants
INTERVENTIONAL
2005-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ropinirole Hydrochloride
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males or females; females of childbearing age who are not currently pregnant must agree to use a medically accepted method of contraception throughout the study.
* Age greater than or equal to 25 years.
* Patients must be on a maximum dose of dopamine agonist drug (pergolide 4mg/day, pramipexole 4.5 mg/day or ropinirole 24mg/day).
* Stable dose of all medications for 4 weeks.
Exclusion Criteria
* History of disabling hallucinations or hallucinations in past requiring treatment.
* Troublesome edema (swelling).
* Unstable depression.
* Female who is pregnant or lactating.
* Use of an investigational drug with in the last 30 days.
25 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Colorado Neurology
OTHER
GlaxoSmithKline
INDUSTRY
Agarwal, Pinky, M.D.
INDIV
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pinky Agarwal, MD
Role: PRINCIPAL_INVESTIGATOR
Colorado Neurology, P.C.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Colorado Neurology, P.C.
Englewood, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
103911
Identifier Type: -
Identifier Source: org_study_id